Next-generation drug conjugates oncology market seen reaching $22.86B by 2030

The Business Research Company says the global next-generation drug conjugates oncology market will rise from $13.88 billion in 2026 to $22.86 billion by 2030, driven by precision oncology, biomarker testing and broader demand for targeted cancer therapies. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - The market is tied to the push for more precise cancer treatment that can attack tumors while limiting damage to healthy tissue. - Faster growth could expand investment in antibody-drug conjugates, targeted biologics and related diagnostics. - The report points to rising cancer incidence as a core demand driver, reinforcing the need for therapies that improve outcomes and reduce toxicity.

What happened: - The Business Research Company said the global next-generation drug conjugates oncology market is projected to grow from $12.28 billion in 2025 to $13.88 billion in 2026. - The company expects the market to reach $22.86 billion by 2030. - The forecast implies a 13.0% CAGR from 2025 to 2026 and a 13.3% CAGR from 2026 to 2030. - The market report was published July 20, 2026, from London. - The company also made available a free sample report and the full market report.

The details: - The report links recent growth to monoclonal antibody therapeutics, a larger global cancer patient population, better management of chemotherapy side effects, faster approvals of targeted biological therapies and more oncology clinical trials. - The report says future growth will come from wider precision oncology adoption, higher investment in biologics and targeted treatment pipelines, more companion diagnostics and biomarker testing, stronger demand in emerging economies and advances in payload design and conjugation methods. - The report identifies key trends including improved linker chemistry, new cytotoxic and immune-modulatory payloads, tumor microenvironment-responsive conjugates, multi-specific and dual-targeting conjugates and broader biomarker-driven patient selection. - Next-generation drug conjugates, including antibody-drug conjugates, are designed to deliver therapeutic agents directly to cancer cells while sparing healthy tissue. - The therapies combine advanced targeting strategies, enhanced payloads and refined delivery technologies to improve efficacy, reduce side effects and address resistant cancers. - The report cites CDC data showing 1,851,238 newly diagnosed cancer cases in the U.S. in 2022 and 613,349 cancer-related deaths in 2023. - The report says North America held the largest market share in 2025. - The report says Asia-Pacific is expected to post the fastest growth during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The 2026 report package adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast suggests the market is moving from broad oncology innovation toward more segmented, biomarker-led treatment models. - The emphasis on payload design, linker chemistry and dual-targeting reflects an industry effort to solve resistance and tumor heterogeneity, two persistent barriers in cancer care. - Asia-Pacific’s projected pace signals where future commercial growth may concentrate as demand for advanced cancer treatment rises outside mature markets.

What's next: - The report expects biomarker testing and companion diagnostics to play a larger role in patient selection. - The company expects continued R&D activity around multi-specific conjugates and tumor-activated therapies. - Further market expansion will likely depend on adoption of precision oncology platforms and continued investment in targeted pipelines.

The bottom line: - The next-generation drug conjugates oncology market is moving into a high-growth phase, with demand shaped by cancer burden, precision medicine and technology advances in drug delivery.